Current partner codePEPTIDESDE
NCT03369262·Phase 2·INTERVENTIONAL

PoC Study of OBE022 in Threatened Preterm Labour

Status

Unknown

Phase

Phase 2

Enrollment

115

Locations

18

Results

Not posted

Publications

1

Study summary

What the protocol is testing.

This is a proof-of-concept study in 2 parts. In Part A, patients will receive OBE022 open-label in order to assess the safety and pharmacokinetics in pregnant women with spontaneous preterm labour with a gestational age between 28 0/7 and 33 6/7 weeks. Part B has a double-blind, randomised, placebo controlled, parallel group and multicentre design and will assess the efficacy, safety and pharmacokinetics in pregnant women with threatened spontaneous preterm labour with a gestational age between 24 0/7 and 33 6/7 weeks. All patients in part A and part B must receive atosiban infusion for 48 hours as standard of care treatment. Patients from Part A will receive OBE022 open label. Patients from Part B will be randomised to receive OBE022 or matching placebo. IMP treatment duration will be up to 7 days. IMP treatment will be stopped in case of delivery prior to Day 7.

Interventions

Treatment arms and agents.

DRUG

OBE022

Oral

DRUG

Placebos

Oral

DRUG

Atosiban

I.V.

Timeline

From registration to results.

  1. First posted

    Dec 11, 2017

  2. Study start

    Jan 10, 2018

  3. Primary completion

    Jul 8, 2020

  4. Study completion

    Aug 2022

  5. Results posted

    Not reported

  6. Registry updated

    Jun 7, 2021

Outcomes

What the study measures.

Primary outcomes

Incidence of delivery within 2 days (48 h) from start of IMP administration

Time frame · 48 hours

Incidence of delivery within 7 days (168 h) from start of IMP administration

Time frame · 168 hours

Incidence of delivery before 37 weeks of GA

Time frame · Up to 13 weeks from start of IMP administration

Time to delivery measured from start of IMP administration

Time frame · Up to 17 weeks from start of IMP administration

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
FEMALE
Healthy volunteers
No

Key Inclusion Criteria: Part A * Pregnant females aged ≥ 18 years * Patients with a singleton or twin pregnancy * Gestational age between 28 0/7 and 33 6/7 * Administered or prescribed atosiban for the treatment of preterm labour Part B * Pregnant females aged ≥ 18 years * Patients with a singleton or twin pregnancy * Gestational age between 24 0/7 and 33 6/7 * Administered or prescribed atosiban for the treatment of preterm labour * ≥4 uterine contractions per 30 minutes * Cervical dilatation of 1 to 4 cm inclusive * At least one of the following signs of preterm labour: 1. positive IGFBP-1 or fœtal Fibronectin test 2. cervical length ≤ 25mm 3. progressive cervical change Key Exclusion Criteria: * Fœtal death in utero in current or previous pregnancy after gestational week 24 or expected high risk of fœtal death in the coming days * Oligohydramnios * Known pathological Doppler ultrasound of the umbilical artery * Any contraindications for the mother or the fœtus to stop labour or prolong pregnancy or any maternal or fœtal conditions likely to indicate iatrogenic delivery in the next 7 days, including but not limited to: 1. Premature rupture of membranes 2. Evidence or suspicion of abruptio placenta 3. Signs and/or symptoms of chorio-amnionitis 4. Pre-eclampsia, eclampsia or HELLP-syndrome * Use of cervical cerclage in the current pregnancy or a pessary in situ * Current use of anti-hypertensive medication * Treatment with other tocolytics within specified time before the baseline assessment of uterine contractions

Study locations

18 registered sites.

Czechia · Finland · Israel · Russia · Spain · Vietnam. Showing up to 24 locations stored in the fast local snapshot.

Gynekologicko-porodnická klinika Fakultní nemocnice Brno

Brno, Czechia

Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze

Prague, Czechia

Ústav pro péči o matku a dítě

Prague, Czechia

Helsinki Universisty Hospital

Helsinki, Finland

Hilel Yafe Medical Center, Maternal Fetal Unit

Haifa, Israel

Rambam Medical Center, Maternal Fetal Unit

Haifa, Israel

Meir Medical Center, Obstetrics and Gynecology Department

Kfar Saba, Israel

Rabin Medical Center, Fetal-Maternal Medicine, Helen Schneider's Hospital for Women

Petah Tikva, Israel

Moscow Regional Perinatal Center

Balashikha, Russia

Kazan State Medical University

Kazan', Russia

City clinical hospital № 15 named after O. M. Filatov of Healthcare Department of Moscow

Moscow, Russia

Perinatal center of the City Clinical Hospital #24

Moscow, Russia

Hospital La Paz

Madrid, Spain

Hospital Clínico Universitario Virgen de la Arrixaca

Murcia, Spain

Hospital Clínico Universitario de Santiago

Santiago de Compostela, Spain

Hospital Universitari i Politècnic La Fe

Valencia, Spain

Hanoi Obstetrics and Gynecology Hospital

Hanoi, Vietnam

My Duc Hospital

Ho Chi Minh City, Vietnam

Related trials

More studies on Atosiban.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.